Related Experiment Video
Updated: Mar 31, 2026
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
Dysregulation of non-coding RNAs in gastric cancer
Qing Yang1, Ren-Wen Zhang1, Peng-Cheng Sui1
1Qing Yang, Ren-Wen Zhang, Peng-Cheng Sui, Hai-Tao He, Lei Ding, Department of Pathogenobiology, College of Basic Medical Sciences, Jilin University, Changchun 130012, Jilin Province, China.
Abstract:
Gastric cancer (GC) is one of the most common cancers in the world and a significant threat to the health of patients, especially those from China and Japan. The prognosis for patients with late stage GC receiving the standard of care treatment, including surgery, chemotherapy and radiotherapy, remains poor. Developing novel treatment strategies, identifying new molecules for targeted therapy, and devising screening techniques to detect this cancer in its early stages are needed for GC patients. The discovery of non-coding RNAs (ncRNAs), primarily microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), helped to elucidate the mechanisms of tumorigenesis, diagnosis and treatment of GC. Recently, significant research has been conducted on non-coding RNAs and how the regulatory dysfunction of these RNAs impacts the tumorigenesis of GC. In this study, we review papers published in the last five years concerning the dysregulation of non-coding RNAs, especially miRNAs and lncRNAs, in GC. We summarize instances of aberrant expression of the ncRNAs in GC and their effect on survival-related events, including cell cycle regulation, AKT signaling, apoptosis and drug resistance. Additionally, we evaluate how ncRNA dysregulation affects the metastatic process, including the epithelial-mesenchymal transition, stem cells, transcription factor activity, and oncogene and tumor suppressor expression. Lastly, we determine how ncRNAs affect angiogenesis in the microenvironment of GC. We further discuss the use of ncRNAs as potential biomarkers for use in clinical screening, early diagnosis and prognosis of GC. At present, no ideal ncRNAs have been identified as targets for the treatment of GC.
Insights
Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are crucial in gastric cancer (GC) development. Their dysregulation impacts tumor progression, metastasis, and treatment resistance, highlighting their potential as diagnostic and prognostic biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer (GC) poses a significant global health threat, with poor prognosis for advanced stages despite standard treatments.
- Non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have emerged as key players in cancer biology.
- Understanding ncRNA dysregulation is vital for developing new diagnostic and therapeutic strategies for GC.
Purpose of the Study:
- To review recent literature (last five years) on the role of dysregulated ncRNAs in gastric cancer.
- To summarize the impact of aberrant ncRNA expression on GC tumorigenesis, progression, and the tumor microenvironment.
- To evaluate the potential of ncRNAs as biomarkers for GC screening, diagnosis, and prognosis.
Main Methods:
- Systematic review of scientific papers published within the last five years.
- Analysis of studies focusing on microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in gastric cancer.
- Synthesis of findings related to ncRNA expression, function, and clinical relevance.
Main Results:
- Aberrant expression of ncRNAs significantly affects GC cell cycle regulation, apoptosis, drug resistance, and AKT signaling.
- ncRNA dysregulation is implicated in GC metastasis, influencing epithelial-mesenchymal transition, stem cell properties, and transcription factor activity.
- ncRNAs play a role in modulating angiogenesis within the GC microenvironment.
Conclusions:
- Dysregulated ncRNAs are deeply involved in multiple facets of gastric cancer development and progression.
- ncRNAs show promise as biomarkers for early detection, diagnosis, and predicting prognosis in GC patients.
- Further research is needed to identify ideal ncRNAs for targeted GC therapy, as none are currently established.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:39lncRNA - Long Non-coding RNAs
01:22MicroRNAs
01:22MicroRNAs
01:37Epigenetic Regulation
X-chromosome...
01:46Epigenetic Regulation